Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ImmusanT
Biotech
ImmusanT cans phase 2 celiac trial after interim efficacy review
The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.
Nick Paul Taylor
Jun 26, 2019 8:52am
ImmusanT to move into Type 1 diabetes with JDRF backing
Sep 11, 2018 8:00am
Chutes and Ladders—Lilly's oncology chief announces retirement
May 25, 2018 9:29am
ImmusanT goes on hiring spree ahead of celiac vaccine trial
May 21, 2018 11:22am
ImmusanT's celiac disease immunotherapy passes first clinical test
Feb 22, 2017 9:27am
